Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Plus Therapeutics
(NASDAQ:PSTV)
Intraday
$1.63
0.03
[1.87%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$1.63
0.03
[1.87%]
Last update: 1:10PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Plus Therapeutics Stock (NASDAQ:PSTV)
Plus Therapeutics Stock (NASDAQ: PSTV)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, April 22, 2024
Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense
Vandana Singh
-
3 days ago
Plus Therapeutics Says 'Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline'
Benzinga Newsdesk
-
3 days ago
Plus Therapeutics Receives $3M Award Recommendation From The U.S. Department Of Defense
Benzinga Newsdesk
-
3 days ago
Monday, March 25, 2024
Plus Therapeutics Announces Validation & Clinical Implementation Of CSF-01 Leptomeningeal Cancer Cell Diagnostic
Benzinga Newsdesk
-
Mar 25, 2024, 8:09AM
Monday, March 11, 2024
Plus Therapeutics Has Completed Dosing In Cohort 5 Of ReSPECT-LM Phase 1 Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases From Solid Tumors; Company Expects Moving Into Cohort 6 In Q2 2024 Following Standard Safety Review
Benzinga Newsdesk
-
Mar 11, 2024, 7:21AM
Tuesday, March 05, 2024
Recap: Plus Therapeutics Q4 Earnings
Benzinga Insights
-
Mar 5, 2024, 4:35PM
Plus Therapeutics Q4 EPS $(0.70) Beats $(1.07) Estimate, Sales $1.31M Beat $1.06M Estimate
Benzinga Newsdesk
-
Mar 5, 2024, 4:30PM
Earnings Scheduled For March 5, 2024
Benzinga Insights
-
Mar 5, 2024, 5:00AM
Monday, March 04, 2024
Plus Therapeutics Earnings Preview
Benzinga Insights
-
Mar 4, 2024, 1:03PM
Monday, December 18, 2023
Plus Therapeutics Says The Award Payment Of $3.3M Together With Its Cash On Hand Provides Sufficient Runway To Fund Operations To 2H 2025
Benzinga Newsdesk
-
Dec 18, 2023, 7:21AM
Tuesday, December 12, 2023
Plus Therapeutics Partners With K2bio To Develop Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
Benzinga Newsdesk
-
Dec 12, 2023, 8:02AM
Monday, November 20, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Nov 20, 2023, 12:31PM
Thursday, November 09, 2023
Insiders Buying Plus Therapeutics And 2 Other Stocks Under $2
Lisa Levin
-
Nov 9, 2023, 8:51AM
Friday, November 03, 2023
Plus Therapeutics Says It Has Been Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda For Breast Cancer Treatment with Leptomeningeal Metastases
Benzinga Newsdesk
-
Nov 3, 2023, 7:05AM
Wednesday, November 01, 2023
Why Plus Therapeutics Stock Popped Today
Ryan Gustafson
-
Nov 1, 2023, 3:38PM
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Nov 1, 2023, 1:59PM
Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Nov 1, 2023, 8:07AM
Tuesday, October 31, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Oct 31, 2023, 5:31PM
Plus Therapeutics shares are trading higher after the company reported Q3 financial results and announced a share repurchase program.
Benzinga Newsdesk
-
Oct 31, 2023, 4:24PM
Plus Therapeutics Announces Share Repurchase Program To Repurchase Up To $500,000 Of Common Stock
Benzinga Newsdesk
-
Oct 31, 2023, 4:20PM
Plus Therapeutics Q3 EPS $(1.00) Vs $(2.85) Last Year, Sales $1.24M Miss $1.29M Estimate
Benzinga Newsdesk
-
Oct 31, 2023, 4:06PM
Earnings Scheduled For October 31, 2023
Benzinga Insights
-
Oct 31, 2023, 5:44AM
Monday, October 30, 2023
Earnings Outlook For Plus Therapeutics
Benzinga Insights
-
Oct 30, 2023, 5:01PM
Monday, October 16, 2023
Why Is Liquid Biopsy Firm Biocept Stock Trading Lower Today?
Vandana Singh
-
Oct 16, 2023, 12:22PM
Tuesday, October 10, 2023
Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
Benzinga Newsdesk
-
Oct 10, 2023, 7:04AM
Friday, September 29, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Sep 29, 2023, 5:31PM
Thursday, September 21, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 21, 2023, 12:08PM
Monday, September 18, 2023
Plus Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Lisa Levin
-
Sep 18, 2023, 8:43AM
Monday, September 11, 2023
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Sep 11, 2023, 1:38PM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Sep 11, 2023, 9:06AM
Plus Therapeutics Receives $1.9 Million Advance Payment From CPRIT; To Present Data From Its ReSPECT-LM Clinical Trial
Benzinga Newsdesk
-
Sep 11, 2023, 7:06AM
Friday, September 08, 2023
Plus Therapeutics shares are trading lower after the company announced a licensing agreement with Biocept.
Benzinga Newsdesk
-
Sep 8, 2023, 3:52PM
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights
-
Sep 8, 2023, 1:31PM
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?
Vandana Singh
-
Sep 8, 2023, 9:18AM
EXCLUSIVE: Plus Therapeutics Tells Benzinga 'As part of the agreement, Plus obtains a nonexclusive license and option for exclusivity for patients receiving CNS radiotherapy'
Benzinga Newsdesk
-
Sep 8, 2023, 6:30AM
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
Vandana Singh
-
Sep 8, 2023, 6:30AM
EXCLUSIVE: Plus Therapeutics Tells Benzinga Co Enters Into License Agreement For Cerebrospinal Fluid Tumor Cell Enumeration Assay
Benzinga Newsdesk
-
Sep 8, 2023, 6:30AM
Tuesday, September 05, 2023
Plus Therapeutics Initiates Part B Of ReSPECT-LM Phase 1/2a Trial For Leptomeningeal Metastase
Benzinga Newsdesk
-
Sep 5, 2023, 7:04AM
Tuesday, August 15, 2023
HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
Benzinga Newsdesk
-
Aug 15, 2023, 7:05AM
Monday, August 14, 2023
Plus Therapeutics Q2 EPS $(0.59) Beats $(1.91) Estimate, Sales $1.85M Beat $790.00K Estimate
Benzinga Newsdesk
-
Aug 14, 2023, 4:36PM
Plus Therapeutics Presents Exciting New Clinical Data At Top Cancer Conference
Johnny Rice
-
Aug 14, 2023, 1:34PM
Earnings Scheduled For August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 6:45AM
HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
Benzinga Newsdesk
-
Aug 14, 2023, 6:35AM
Friday, August 11, 2023
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Aug 11, 2023, 1:47PM
Plus Therapeutics Earnings Preview
Benzinga Insights
-
Aug 11, 2023, 1:02PM
EXCLUSIVE: Plus Therapeutics Tells Benzinga 'FDA approves continuation to Phase 1 Part B of the ReSPECT-LM clinical trial'
Benzinga Newsdesk
-
Aug 11, 2023, 6:00AM
EXCLUSIVE: Plus Therapeutics Tells Benzinga 'Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases'
Benzinga Newsdesk
-
Aug 11, 2023, 6:00AM
EXCLUSIVE: Plus Therapeutics Tells Benzinga Co Reports ReSPECT-LM Phase I Trial Data At The 2023 SNO/ASCO CNS Cancer Conference
Benzinga Newsdesk
-
Aug 11, 2023, 6:00AM
EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer
Vandana Singh
-
Aug 11, 2023, 6:00AM
Wednesday, July 26, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Jul 26, 2023, 5:32PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch